基于PLGA纳米粒的SARS-CoV-2 DNA疫苗的制备及初步评价
Preparation and preliminary evaluation of SARS-CoV-2 DNA vaccine based on PLGA nanoparticles
-
摘要: 本研究构建并优化编码新型冠状病毒(severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)刺突(spike protein, S)蛋白基因序列的质粒DNA (plasmid DNA, pDNA)Opt-S, 以聚乳酸-羟基乙酸共聚物poly (lactic-co-glycolic acid), PLGA 纳米粒(nanoparticles, NPs)作为pDNA的递送载体, 采用纳米沉淀法制备PLGA-pDNA NPs, 对其体外性质进行初步评价。结果表明所制备的PLGA-pDNA NPs形态规整, 边缘清晰, 平均粒径为(184.2 ± 2.4) nm, 多分散系数(polydisperse index, PDI) 为0.093 ± 0.013, zeta电位为(-68.10 ± 0.36) mV, 包封率为(98.92 ± 0.22)%, 于-20 ℃储存7个月粒径和PDI变化幅度均较小, 稳定性较好, 能保护pDNA免受核酸酶降解, 并具有一定的缓释效果, 细胞毒性低, 安全性高, 体外转染实验表明SARS-CoV-2 S基因可以进入细胞并表达。以上结果表明PLGA-pDNA NPs非病毒基因载体制备工艺简单、性能良好, 有望为SARS-CoV-2疫苗研发提供新思路。Abstract: We constructed and optimized the plasmid DNA (pDNA) Opt-S encoding the gene of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, using poly (lactic-co-glycolic acid) copolymer (PLGA) as a delivery carrier for pDNA. PLGA-pDNA NPs were loaded by nanoprecipitation and its properties in vitro were preliminary evaluated. The results showed that the prepared PLGA-pDNA NPs were regular morphology, clear edges, with an average particle size of (184.2 ± 2.4) nm, polydisperse index (PDI) of 0.093 ± 0.013, zeta potential of (-68.10 ± 0.36) mV, and encapsulation rate of (98.92 ± 0.22)%. The PLGA-pDNA NPs were stable at -20 ℃ for 7 months and could protect pDNA against nuclease degradation. And they also exhibited sustained release of pDNA in vitro. The PLGA-pDNA NPs have low cytotoxicity and high safety. In addition, in vitro transfection experiments showed that the SARS-CoV-2 S gene could enter cells and be expressed. These results indicate that PLGA-pDNA NPs non-viral gene vector have simple preparation process and good performance, which are expected to provide a new idea for the research and development of SARS-CoV-2 vaccine.
下载: